{
    "clinical_study": {
        "@rank": "16834", 
        "arm_group": [
            {
                "arm_group_label": "10\u00b5g/0.5ml hepatitis B vaccine", 
                "arm_group_type": "Experimental", 
                "description": "3 dose of 10\u00b5g/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number: YHB2008063S1."
            }, 
            {
                "arm_group_label": "5\u00b5g/0.5ml hepatitis B vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "3 dose of 5\u00b5g/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number:20080603."
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of this study was to evaluate the safety and immunogenicity of 10\u00b5g/0.5ml\n      and 5\u00b5g/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in\n      saccharomyces cereviside yeast for infants and other age groups."
        }, 
        "brief_title": "Study of Evaluating Safety and Immunogenicity of 10\u00b5g/0.5ml Hepatitis B Vaccine", 
        "completion_date": {
            "#text": "October 2010", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (For Infant Group):\n\n          -  Healthy full-term infant after birth, Apgar score \u22657.\n\n          -  Guardian signed informed consent.\n\n          -  Guardian can comply with the requirements of the clinical trial.\n\n          -  Without administering immunoglobulin during the following period.\n\n          -  Axillary temperature \u226437.0 \u2103.\n\n        Inclusion Criteria (For Other Age Groups):\n\n          -  More than 1 month old healthy people, without the history of hepatitis B infection.\n\n          -  Subjects or their guardians signed informed consent.\n\n          -  After questioning medical history, physical examination and being judged as healthy\n             subject.\n\n          -  Without the history of hepatitis B vaccination.\n\n          -  Subjects or their guardians can comply with requirements of the clinical trail.\n\n          -  Without other prevention drugs or immunoglobulin administered within two weeks before\n             the clinical trail or during the following period.\n\n          -  Axillary temperature \u226437.0 \u2103.\n\n        Exclusion Criteria (For Infant Group):\n\n          -  Apgar score of infant after birth <7.\n\n          -  With nervous system damage after birth, or with the family history of mental illness,\n             epilepsy or encephalopathy.\n\n          -  With immune system dysfunction.\n\n          -  With vitamin deficiency.\n\n          -  With acute febrile diseases, or infectious diseases.\n\n          -  With congenital malformations, developmental disorders or serious chronic illness.\n\n          -  With thrombocytopenia or other coagulation disorders.\n\n          -  Administered immunoglobulin during the period of the clinical trail, especially\n             administered Hepatitis B immunoglobulin to the infant of Hepatitis B infected mother.\n\n          -  With endemic disease.\n\n          -  Participate another clinical trial during the period of the clinical trail.\n\n          -  Any circumstance that may affect clinical trail evaluation.\n\n        Exclusion Criteria (For Other Age Groups):\n\n          -  With allergies, seizures, epilepsy, encephalopathy or with family history of mental\n             illness.\n\n          -  Allergic to any component of the study vaccine.\n\n          -  With immune system dysfunction.\n\n          -  Hepatitis B infected people.\n\n          -  Anti-HBs was positive screened by ELISA kit.\n\n          -  Either anti-HBs \u226510mIU/ml or HBsAg was positive screened by Radioimmunoassay method.\n\n          -  With acute febrile diseases or infectious diseases.\n\n          -  With congenital malformations, developmental disorders or serious chronic illness.\n\n          -  With thrombocytopenia or other coagulation disorders.\n\n          -  With the history of severe allergic reactions.\n\n          -  Administered other prevention drugs or immunoglobulin within two weeks before the\n             clinical trail or during the following period.\n\n          -  With any acute illness that requires antibiotics or anti-viral treatment within 7\n             days before the clinical trail.\n\n          -  With vitamin deficiency.\n\n          -  With the history of febrile convulsion.\n\n          -  Axillary temperature \u226538.0 \u2103 within 3 days before the clinical trail.\n\n          -  Participate another clinical trial during the period of the clinical trail.\n\n          -  Pregnant woman.\n\n          -  Any circumstance that may affect clinical trail evaluation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "1537", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152709", 
            "org_study_id": "JSEPI-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "10\u00b5g/0.5ml hepatitis B vaccine", 
                "description": "3 dose of 10\u00b5g/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.", 
                "intervention_name": "3 dose of 10\u00b5g/0.5ml hepatitis B vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "5\u00b5g/0.5ml hepatitis B vaccine", 
                "description": "3 dose of 5\u00b5g/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.", 
                "intervention_name": "3 dose of 5\u00b5g/0.5ml hepatitis B vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety", 
            "Immunogenicity", 
            "Vaccine", 
            "Hepatitis B"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210009"
                }, 
                "name": "Jiangsu Provincial Center for Disease Control and Prevention"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized, Controlled, and Blinded Clinical Trial to Evaluate Safety and Immunogenicity of 10\u00b5g/0.5ml Hepatitis B Vaccine for Infants and Other Age Groups.", 
        "overall_official": {
            "affiliation": "Jiangsu Provincial Center for Disease Control and Prevention", 
            "last_name": "Fubao Ma, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To analyze the number of subjects with adverse events within 28 days after administered each of hepatitis B vaccine.", 
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Within 28 days after hepatitis B vaccination"
            }, 
            {
                "description": "Geometric mean concentration of anti-hepatitis B virus surface antigen antibody  was measured by chemiluminescence assay and expressed with mIU/mL.", 
                "measure": "Geometric mean concentration of anti-hepatitis B virus surface antigen antibody", 
                "safety_issue": "No", 
                "time_frame": "The 28th day after whole course of hepatitis B vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152709"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To analyze the rate of hepatitis B virus perinatal transmission after whole course of hepatitis B vaccination.", 
                "measure": "The rate of hepatitis B virus perinatal transmission", 
                "safety_issue": "No", 
                "time_frame": "The 28th day after whole course of hepatitis B vaccination"
            }, 
            {
                "description": "Geometric mean concentration of anti-hepatitis B virus surface antigen antibody  was measured by chemiluminescence assay and expressed with mIU/mL.", 
                "measure": "Geometric mean concentration of anti-hepatitis B virus surface antigen antibody after the second  dose of hepatitis B vaccination", 
                "safety_issue": "No", 
                "time_frame": "The 28th day after the second of hepatitis B vaccination"
            }
        ], 
        "source": "Jiangsu Province Centers for Disease Control and Prevention", 
        "sponsors": {
            "collaborator": {
                "agency": "Beijing Tiantan Biological Products Co., Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu Province Centers for Disease Control and Prevention", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}